Skip to main content

Table 5 Time to first response (days) in intention-to-treat population, according to initial masitinib dosage

From: Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

Parameter 3 mg/kg per day
(n = 22)
6 mg/kg per day
(n = 18)
Total population
(n = 40)
P value
ACR20     
   Patients 12/22 (55.0%) 11/18 (61.0%) 23/40 (57.5%) 0.213
   Mean ± SD 51.9 ± 24.5 40.3 ± 19.0 46.3 ± 22.4  
   Median 56.0 29.0 35.0  
   Range 28.0–105.0 28.0–86.0 28.0–105.0  
ACR50     
   Patients 7/22 (32.0%) 8/18 (44.0%) 15/40 (37.5%) 0.771
   Mean ± SD 91.9 ± 59.5 86.8 ± 61.1 89.1 ± 58.2  
   Median 84.0 72.5 84.0  
   Range 28.0–217.0 28.0–203.0 28.0–217.0  
  1. ACR20, American College of Rheumatology 20% improvement criteria; ACR50, American College of Rheumatology 50% improvement criteria; SD, standard deviation.